
## Yuxian Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2362994/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DIC Score Combined With CLIF-C OF Score Is More Effective in Predicting Prognosis in Patients With Hepatitis B Virus Acute-on-Chronic Liver Failure. Frontiers in Medicine, 2022, 9, 815580.	1.2	2
2	Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients. Emerging Microbes and Infections, 2022, 11, 1586-1601.	3.0	7
3	<i>STAT4</i> genetic polymorphism significantly affected HBeAg seroconversion in HBeAgâ€positive chronic hepatitis B patients receiving Peginterferonâ€Î± therapy: A prospective cohort study in China. Journal of Medical Virology, 2022, 94, 4449-4458.	2.5	4
4	A Stepwise Evaluation of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure to Optimize the Indication for Urgent Liver Transplantation. Digestive Diseases and Sciences, 2021, 66, 284-295.	1.1	7
5	Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB. Hepatology International, 2021, 15, 51-59.	1.9	4
6	Baseline serum exosomeâ€derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon. Journal of Medical Virology, 2021, 93, 4939-4948.	2.5	7
7	The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study. Infectious Diseases of Poverty, 2021, 10, 44.	1.5	2
8	Role of Immune Dysfunction in Acute-on-Chronic Liver Failure: From Pathogenesis to Clinical Prognosis Discovery Medicine, 2021, 31, 21-29.	0.5	0
9	Using Next-generation Sequencing to Identify Novel Exosomal miRNAs as Biomarkers for Significant Hepatic Fibrosis Discovery Medicine, 2021, 31, 147-158.	0.5	1
10	Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study. Infectious Diseases and Therapy, 2020, 9, 823-836.	1.8	65
11	Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection. Discovery Medicine, 2020, 29, 119-128.	0.5	0
12	Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naÃ <sup>-</sup> ve chronic hepatitis B patients. Journal of Viral Hepatitis, 2019, 26, 59-68.	1.0	1
13	Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathogens, 2019, 15, e1007690.	2.1	54
14	Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?. Journal of Hepatology, 2018, 68, 609-610.	1.8	4
15	Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. Journal of Hepatology, 2018, 68, 16-24.	1.8	86
16	Globulin–platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels. Clinical and Experimental Medicine, 2018, 18, 71-78.	1.9	12
17	Reply to: "HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient― Journal of Hepatology, 2018, 68, 849-851.	1.8	13
18	Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients. Journal of Virology, 2018, 92, .	1.5	45

Yuxian Huang

#	Article	IF	CITATIONS
19	Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection. Scientific Reports, 2017, 7, 5429.	1.6	6
20	The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. Oncotarget, 2017, 8, 28641-28649.	0.8	28
21	Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget, 2017, 8, 45768-45776.	0.8	13
22	Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels. Oncotarget, 2017, 8, 86463-86470.	0.8	6
23	The independent predictors of significant liver histological changes in chronic hepatitis B virus infection patients with persistently high-normal or low-normal alanine transaminase levels. Discovery Medicine, 2017, 23, 19-25.	0.5	7
24	Cylindromatosis (CYLD) inhibits Streptococcus pneumonia -induced plasminogen activator inhibitor-1 expression via interacting with TRAF-6. Biochemical and Biophysical Research Communications, 2015, 463, 942-947.	1.0	4
25	Epidemiology and the prognosis of healthcare–associated infective endocarditis in China: the significance of non-nosocomial acquisition. Emerging Microbes and Infections, 2015, 4, 1-6.	3.0	19
26	Partial virological response to entecavir treatment in nucleos(t)ide-naÃ⁻ve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. Biochemical and Biophysical Research Communications, 2015, 464, 1185-1191.	1.0	3
27	CYLD Negatively Regulates Nontypeable Haemophilus influenzae-Induced IL-8 Expression via Phosphatase MKP-1-Dependent Inhibition of ERK. PLoS ONE, 2014, 9, e112516.	1.1	14
28	Transcription of Hepatitis B Virus Covalently Closed Circular DNA Is Regulated by CpG Methylation during Chronic Infection. PLoS ONE, 2014, 9, e110442.	1.1	71
29	Immunomodulatory Activity of a Novel, Synthetic Beta-glucan (Î <sup>2</sup> -glu6) in Murine Macrophages and Human Peripheral Blood Mononuclear Cells. PLoS ONE, 2013, 8, e80399.	1.1	13
30	CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nature Communications, 2012, 3, 771.	5.8	128
31	Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections. Immunity, 2007, 27, 349-360.	6.6	127